Rituximab in Combination with High-dose Methylprednisolone for the Treatment of Fludarabine Refractory High-risk Chronic Lymphocytic Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2008 Aug 30

PMID 18754025

Citations 39

Authors

J E Castro

J D Sandoval-Sus

J Bole

L Rassenti

T J Kipps

Affiliations

Soon will be listed here.

Abstract

We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days). All patients were refractory to fludarabine and 86% had high-risk disease by the modified Rai classification. In all, 79% of the patients had CLL cells that expressed ZAP-70 and three patients had poor prognostic cytogenetics. The overall response rate was 93% and the complete remission rate was 36%. The median time-to-progression was 15 months and the median time-to-next treatment was 22 months. Median survival has not been reached after a median follow up of 40 months. Four patients have died of progressive disease. Patients tolerated the treatment well and serious adverse events were rare. This allowed patients to receive all planned treatments on schedule with no dose modifications. All but one patient responded to treatment and the overall survival and time-to-progression were superior to those of other published salvage regimens.

Citing Articles

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.

Mouhssine S, Maher N, Kogila S, Cerchione C, Martinelli G, Gaidano G Hematol Rep. 2024; 16(2):270-282.

PMID: 38804280 PMC: 11130833. DOI: 10.3390/hematolrep16020027.

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.

Nguyen T, Nhu N, Tran V, Viet-Nhi N, Ho X, Jhan M Sci Rep. 2023; 13(1):9775.

PMID: 37328530 PMC: 10276018. DOI: 10.1038/s41598-023-36279-x.

Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies.

Scheijen B Cancer Drug Resist. 2022; 2(3):647-664.

PMID: 35582582 PMC: 8992511. DOI: 10.20517/cdr.2019.29.

NKp30 - A prospective target for new cancer immunotherapy strategies.

Pinheiro P, Justino G, Marques M Br J Pharmacol. 2020; 177(20):4563-4580.

PMID: 32737988 PMC: 7520444. DOI: 10.1111/bph.15222.

Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S Nat Rev Clin Oncol. 2020; 17(5):313-326.

PMID: 32066936 DOI: 10.1038/s41571-019-0319-9.

References

Seymour J, Robertson L, OBrien S, Lerner S, Keating M . Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma. 1995; 18(5-6):493-6. DOI: 10.3109/10428199509059650. View

Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch H . Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001; 114(2):342-8. DOI: 10.1046/j.1365-2141.2001.02959.x. View

Thornton P, Hamblin M, Treleaven J, Matutes E, Lakhani A, Catovsky D . High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma. 1999; 34(1-2):167-70. DOI: 10.3109/10428199909083393. View

Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2001; 343(26):1910-6. DOI: 10.1056/NEJM200012283432602. View

Byrd J, Peterson B, Morrison V, Park K, Jacobson R, Hoke E . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2002; 101(1):6-14. DOI: 10.1182/blood-2002-04-1258. View

Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S . Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35(1):1-39. PMC: 2025310. DOI: 10.1038/bjc.1977.1. View

Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno A, Capelli G . Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001; 98(9):2633-9. DOI: 10.1182/blood.v98.9.2633. View

Cheson B, Bennett J, Grever M, Kay N, Keating M, OBrien S . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12):4990-7. View

Rai K . Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol. 2006; 33(2 Suppl 5):S15-22. DOI: 10.1053/j.seminoncol.2006.01.025. View

10.

OBrien S, Kantarjian H, Cortes J, Beran M, Koller C, Giles F . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19(5):1414-20. DOI: 10.1200/JCO.2001.19.5.1414. View

11.

Ravandi F, OBrien S . Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2005; 55(2):197-209. PMC: 11029864. DOI: 10.1007/s00262-005-0015-8. View

12.

Tsukada N, Burger J, Zvaifler N, Kipps T . Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002; 99(3):1030-7. DOI: 10.1182/blood.v99.3.1030. View

13.

Keating M, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B . Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989; 74(1):19-25. View

14.

Rassenti L, Huynh L, Toy T, Chen L, Keating M, Gribben J . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351(9):893-901. DOI: 10.1056/NEJMoa040857. View

15.

OBrien S, Kantarjian H, Thomas D, Giles F, Freireich E, Cortes J . Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19(8):2165-70. DOI: 10.1200/JCO.2001.19.8.2165. View

16.

Thornton P, Matutes E, Bosanquet A, Lakhani A, Grech H, Ropner J . High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003; 82(12):759-65. DOI: 10.1007/s00277-003-0710-5. View

17.

Byrd J, Murphy T, Howard R, Lucas M, Goodrich A, Park K . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001; 19(8):2153-64. DOI: 10.1200/JCO.2001.19.8.2153. View

18.

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

19.

Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N . Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002; 119(4):976-84. DOI: 10.1046/j.1365-2141.2002.03959.x. View

20.

Rai K, Freter C, Mercier R, Cooper M, Mitchell B, Stadtmauer E . Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002; 20(18):3891-7. DOI: 10.1200/JCO.2002.06.119. View